News briefing: FDA lifts a hold on Poseida study; Decibel adopts 2-AAV approach to hearing loss; AstraZeneca partners on combos, again
A little more than 2 months ago, shares of newly public Poseida Therapeutics $PSTX cratered after the biotech reported that a patient death had spurred the FDA to drop a full hold on its lead cancer drug. This morning we learned that regulators lifted the hold, but details are sparse.
In a statement out early Monday, Poseida said that regulators had lifted the hold on their Phase I study for their CAR-T P-PSMA-101 in prostate cancer. Here’s why:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.